Natural history of hepatitis C in HIV-negative patients with congenital coagulation disorders

Meijer, Karina; Haagsma, Elizabeth B.; Kok, T; Schirm, J; Smid, WM; Meer, Jan van der

doi:10.1016/s0168-8278(99)80029-4

Cited by 20 publications

(28 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The average time lapse between the infection and the onset of liver cirrhosis was 21.6 years (range, . Among the 12 patients with liver cirrhosis, 4 patients (4.5%) developed hepatic decompensation after an average period of 4.3 years (range, 2-8) from the onset of liver cirrhosis and 27.5 years (range, [23][24][25][26][27][28][29][30][31][32] from the HCV infection, respectively. Two patients (2.3%) with liver cirrhosis developed HCC 4 and 8 years, respectively, after the diagnosis of liver cirrhosis (29 and 32 years from the HCV infection).…”

Section: Resultsmentioning

confidence: 99%

“…2,3,7 Because the onset of infection can be reasonably estimated (first treatment with non-virus-inactivated blood products), these patients represent a unique model for studying the natural history of HCV infection and associated complications. [22][23][24][25] The course of hepatitis can be accurately assessed in these patients because of the long-term follow-up and because they are seen regularly throughout their life at hemophilia centers with laboratory, clinical, and instrumental tests.…”

Section: Discussionmentioning

confidence: 99%

“…Thus, our data are similar to those reported in literature 9,14-18 for non-hemophilic HCV-infected patients and confirm the slow progression of HCV infection in HIV-seronegative hemophiliacs. 24,25 Genotype 1 was the most frequent among HCV genotypes (Table 1). In fact, it was detected, alone, or associated with other genotypes in 63.6% of cases.…”

Section: Discussionmentioning

confidence: 99%

“…[21][22][23][24][25] Furthermore, most of the few studies published so far refer to hemophiliacs coinfected with HIV, [26][27][28][29][30] which is a well-known risk factor for a more rapid progression of liver disease and could be a confounding factor in evaluating the natural history of HCV infection.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

The natural history of chronic hepatitis C in a cohort of HIV-negative Italian patients with hereditary bleeding disorders

Franchini

Rossetti

Tagliaferri

et al. 2001

Blood

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The natural history of chronic hepatitis C in a cohort of HIV-negative Italian patients with hereditary bleeding disorders

Franchini

Rossetti

Tagliaferri

et al. 2001

Blood

View full text Add to dashboard Cite

“…With peri-procedural factor VIII supplementation, TIPS have been placed without complications and the outcomes appear to be comparable to those in patients without haemophilia [225][226][227][228].…”

Section: Haemophiliamentioning

confidence: 99%

Consensus conference on TIPS management: Techniques, indications, contraindications

Fagiuoli

Bruno

Venon

et al. 2017

Digestive and Liver Disease

130

120

View full text Add to dashboard Cite

a b s t r a c tThe trans jugular intrahepatic Porto systemic shunt (TIPS) is no longer viewed as a salvage therapy or a bridge to liver transplantation and is currently indicated for a number of conditions related to portal hypertension with positive results in survival. Moreover, the availability of self-expandable polytetrafluoroethylene (PTFE)-covered endoprostheses has dramatically improved the long-term patency of TIPS. However, since the last updated International guidelines have been published (year 2009) new evidence have come, which have open the field to new indications and solved areas of uncertainty. On this basis, the Italian Association of the Study of the Liver (AISF), the Italian College of Interventional Radiology-Italian Society of Medical Radiology (ICIR-SIRM), and the Italian Society of Anesthesia, Analgesia and Intensive Care (SIAARTI) promoted a Consensus Conference on TIPS. Under the auspices of the three scientific societies, the consensus process started with the review of the literature by a scientific board of experts and ended with a formal consensus meeting in Bergamo on June 4th and 5th, 2015. The final statements presented here were graded according to quality of evidence and strength of recommendations and were approved by an independent jury. By highlighting strengths and weaknesses of current indications to TIPS, the recommendations of AISF-ICIR-SIRM-SIAARTI may represent the starting point for further studies.

show abstract

Treatment of hepatitis C in hemophiliacs

2006

View full text Add to dashboard Cite

Hepatitis C virus (HCV) infection is a major cause of morbidity and mortality in hemophiliacs who received nonvirucidally treated large-pool clotting factor concentrates before 1986. In fact, although many hemophiliacs infected with HCV have a slow progression of liver disease, in a minority of them hepatitis evolves toward end-stage liver disease and hepatocarcinoma. Moreover, a significant percentage of HCV-infected hemophiliacs were also coinfected with human immunodeficiency virus (HIV), which can accelerate the progression of liver disease. Thus, the aim of anti-HCV therapy is to interrupt the chronic infection in order to prevent the progression of hepatitis to cirrhosis, liver decompensation, cancer and, ultimately, death. In this review we present the literature data on anti-HCV treatment in hemophiliacs. Combination therapy with interferon (IFN) and ribavirin has improved the poor results obtained with IFN monotherapy and has become the standard treatment of chronic hepatitis C. Given the positive results obtained with pegylated interferon plus ribavirin in nonhemophiliacs, ongoing trials are evaluating this promising therapy in HCV-chronically infected hemophilic patients; preliminary results show a sustained response rate similar to that in patients without coagulopathy. Finally, based on the encouraging results in coinfected nonhemophiliacs, anti-HCV treatment should also be considered for those HIV-positive hemophiliacs in whom anti-retroviral treatment has stabilized the HIV infection. Am. J. Hematol.

show abstract

Natural history of hepatitis C in HIV-negative patients with congenital coagulation disorders

Cited by 20 publications

References 33 publications

The natural history of chronic hepatitis C in a cohort of HIV-negative Italian patients with hereditary bleeding disorders

The natural history of chronic hepatitis C in a cohort of HIV-negative Italian patients with hereditary bleeding disorders

Consensus conference on TIPS management: Techniques, indications, contraindications

Treatment of hepatitis C in hemophiliacs

Contact Info

Product

Resources

About